Oncology

December 4th 2023

Pirtobrutinib is the first and only non-covalent BTK inhibitor to be approved by the FDA and is indicated for adult patients who already received at least 2 prior lines of therapy.

December 1st 2023

If approved, this combination will become a first-line treatment option for patients who are cisplatin eligible.

November 30th 2023

Further research is necessary to better understand the development and factors that contribute to CBC after PBC treatment.

November 30th 2023

This is KRP203’s second Orphan Drug Designation and it is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers.